VisilizuMab

Names

[ CAS No. ]:
219716-33-3

[ Name ]:
VisilizuMab

[Synonym ]:
VISILIZUMAB

Biological Activity

[Description]:

Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research[1].

[Related Catalog]:

Signaling Pathways >> Apoptosis >> Apoptosis

Research Areas >> Inflammation/Immunology

[In Vitro]

Visilizumab 诱导固有层 T 细胞的剂量和时间依赖性细胞凋亡。Visilizumab 诱导固有层 T 细胞凋亡依赖于半胱天冬酶 3 和 8，而不是半胱天冬酶 9 的激活，并且不涉及 Fas/FasL 通路[1]。 Apoptosis Analysis[1] Cell Line: Lamina propria T cells Concentration: 1 ng/mL, 10 ng/mL, 100 ng/mL, 1000 ng/mL, 10000 ng/mL Incubation Time: 2 hours, 4 hours, 20 hours, 24 hours, 48 hours Result: Induced dose- and time-dependent apoptosis of lamina propria T cells.

[References]

[1]. Qi T Yu, et al. Visilizumab induces apoptosis of mucosal T lymphocytes in ulcerative colitis through activation of caspase 3 and 8 dependent pathways. Clin Immunol. 2008 Jun;127(3):322-9.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.